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Abstract
Non-gonococcal urethritis (NGU), or inflammation of the urethra, is the most common treatable sexually
transmitted syndrome in men, with approximately 20-50 % of cases being due to infection with Chlamydia
trachomatis and 10-30 % Mycoplasma genitalium. Other causes are Ureaplasma urealyticum, Trichomonas vaginalis,
anaerobes, Herpes simplex virus (HSV) and adenovirus. Up to half of the cases are non-specific. Urethritis is
characterized by discharge, dysuria and/or urethral discomfort but may be asymptomatic. The diagnosis of urethritis
is confirmed by demonstrating an excess of polymorpho-nuclear leucocytes (PMNLs) in a stained smear. An excess
of mononuclear leucocytes in the smear indicates a viral etiology. In patients presenting with symptoms of
urethritis, the diagnosis should be confirmed by microscopy of a stained smear, ruling out gonorrhea. Nucleid acid
amplifications tests (NAAT) for Neisseria gonorrhoeae, C. trachomatis and for M. genitalium. If viral or protozoan
aetiology is suspected, NAAT for HSV, adenovirus and T. vaginalis, if available. If marked symptoms and urethritis is
confirmed, syndromic treatment should be given at the first appointment without waiting for the laboratory results.
Treatment options are doxycycline 100 mg x 2 for one week or azithromycin 1 gram single dose or 1,5 gram
distributed in five days. However, azithromycin as first line treatment without test of cure for M. genitalium and
subsequent Moxifloxacin treatment of macrolide resistant strains will select and increase the macrolide resistant
strains in the population. If positive for M. genitalium, test of cure samples should be collected no earlier than three
weeks after start of treatment. If positive in test of cure, moxifloxacin 400 mg 7–14 days is indicated. Current
partner(s) should be tested and treated with the same regimen. They should abstain from intercourse until both
have completed treatment. Persistent or recurrent NGU must be confirmed with microscopy. Reinfection and
compliance must be considered. Evidence for the following recommendations is limited, and is based on clinical
experience and guidelines. If doxycycline was given as first therapy, azithromycin five days plus metronidazole
4–500 mg twice daily for 5–7 days should be given. If azithromycin was prescribed as first therapy, doxycycline
100 mg x 2 for one week plus metronidazole, or moxifloxacin 400 mg orally once daily for 7–14 days should be
given.
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Macrolide resistance
Urethritis, or urethral inflammation, is in the majority of
cases caused by sexually transmitted agents. Typical
symptoms are discharge, dysuria, urethral stinging/itch-
ing and penile tip irritation, but urethritis is often
asymptomatic [1].
The diagnosis should be confirmed with microscopy of
a stained smear from urethra, demonstrating an excess
of polymorphonuclear leucocytes (PMNLs) or mono-
cytes in the anterior urethra [1]. Urethritis may be
gonococcal, when Neisseria gonorrhoeae is detected or
non-gonococcal (NGU). Mucopurulent non-gonococcal
cervicitis and urethritis is the female equivalent [2–4].
However, the definition of cervicitis and female ureth-
ritis is controversial [4].
Aetiology
Chlamydia trachomatis is, in most settings, the only
aetiological bacterial agent causing urethritis which is
routinely tested for, and isolated in 20–50 % [5].
Mycoplasma genitalium has emerged as the second most
common aetiological agent, causing 10–30 % of cases
[5–7], with a double infection with C. trachomatis in 5
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to 15 % [8]. In 30–60 % of the cases with NGU neither C.
trachomatis nor M. genitalium is detected [9, 10]. Patho-
gen negative NGU is more likely with increasing age, the
absence of discharge or clinical symptoms, and engage-
ment in low-risk practices [9–11].
In Western Europe, Trichomonas vaginalis as a cause of
male urethritis is uncommon [12]. In the United States, T.
vaginalis is associated with Afro-American race, with
prevalences of 2.5–17 [11, 13, 14]. Ureaplasmas are incon-
sistently associated with NGU [15]. Earlier studies did not
differentiate between the two species Ureaplasma urealy-
ticum (biovar 2) and U. parvum (biovar 1). There is in-
creasing evidence that U. parvum is non-pathogenic, and
only U. urealyticum is pathogenic in some men but not all
men colonized in the urethra [16–18]. The immune re-
sponse may influence the development of NGU as in one
study an association of U. urealyticum with NGU was only
observed in men with fewer lifetime sex partners com-
pared to those who had many [17]. Inoculation with U.
urealyticum has been shown to give urethritis symptoms
[19]. Higher organism load (>1000 copies/ml of FVU) of
U. urealyticum may be a predictor of NGU [20]. U. urea-
lyticum may account for 5–10 % of cases of acute NGU,
but is often detected without urethritis, and therefore
screening and test of cure for this micro-organism is ques-
tionnable [21]. Adenoviruses may account for 2–4 % of
symptomatic patients and this is often associated with
conjunctivitis [22–24]. Herpes simplex viruses types 1 and
2 are uncommon causes of NGU (2–3 %) in the absence
of typical genital ulceration [24]. If aetiology of the ureth-
ritis is viral, monocytes are present in the microscopical
smear [23]. N. meningitidis, Haemophilus sp., Candida sp.,
urethral stricture and foreign bodies have all been re-
ported in a few cases and probably account for a small
proportion of NGU, whilst the role of Epstein Barr Virus
is questionable [25, 26]. There is emerging evidence that
bacterial vaginosis-associated bacteria may be associated
with NGU [27]. It is unclear what causes organism-
negative NGU or idiopathic urethritis. Some idiopathic
cases are almost certainly non-infective, but we do not
currently have the tools to be able to differentiate probably
non-infective from likely infective cases [28]. With mod-
ern techniques a diverse microbiome can be detected in
the male urethra, and there may still be unknown bacteria
causing urethritis [28, 29].
Clinical features and signs
Symptomatic patients and, if observed, those with a vis-
ible discharge should be assessed for the presence of ur-
ethritis. The discharge is mucopurulent and often sparse,
but may be cloudy or clear. An excessive purulent dis-
charge should arouse suspicion of gonorrhoea.
Formally, the definition of urethritis diagnosis is micro-
scopically, demonstrating ≥5 PMNL per high power
(x1000) microscopic field (averaged over five fields with
greatest concentration of PMNLs) [30] in a stained smear
from the anterior urethra. This should be performed in
the office as guidance for immediate treatment, without
waiting for the laboratory results.
Gram stain is used in most countries. Methylene blue
stain, which is much more rapid and easier to perform in
the examination room, is used in the Nordic countries [6].
Differentiating gonococcal urethritis from NGU has been
shown to be equal with the two staining methods [31].
The quality of the smear is heavily dependent on how the
smear is taken and there is both inter- and intra-observer
variation when interpreting the result [32, 33]. A 1–5 mm
plastic loop, a sterile blunt spatula or cotton or rayon
tipped swab can be used. The smear should be taken about
0.5 to 1 cm into the urethra. A plastic loop is less painful
than a Dacron swab, which is less painful than a Rayon
swab [34]. Based on reported sensitivities of microscopy for
detection of CT, blunt spatula is better than swab [35, 36].
If a urethral discharge is present and can be adequately
sampled without placing the loop, spatula or swab inside
the meatus, this would be the recommended method for
preparing a smear as it is likely to be preferred by the pa-
tient [37]. However, this has not been compared to the
standard technique in a clinical trial.
Traditionally, a cut-off of 5 PMNL/high power field
microscopy (HPF) has been used for the diagnosis of ur-
ethritis, but this has recently been questioned. A high
prevalence of Chlamydia trachomatis has been observed
in cases of low-grade urethritis with 3–5 PMNL/HPF
[36, 37]. However, a possible reason for the low sensi-
tivity in these studies may be the sampling methods,
using a swab or un-identified device instead of a spatula
[6, 24, 35–37].
Investigations
All cases of urethritis should be screened for C. tracho-
matis by NAAT on first void urine. N. gonorrhoeae must
be ruled out with urethral smear microscopy, NAAT and
culture. In addition, if available, specific test for M. geni-
talium should be taken, preferably including test for
macrolide resistance of M. genitalium [38]. If suspected
because of clinical or epidemiological reasons, tests for
Trichomonas vaginalis, adenovirus and HSV should also
be included.
Men who have sex with men (MSM) should be tested
for C. trachomatis and N. gonorrhoeae from any poten-
tially exposed site [39]. All tests positive for C. trachomatis
from the rectum in MSM should, if possible, be subtyped
for lympho-granuloma venereum.
The first void urine should not contain more than
10 ml, a higher volume will decrease the sensitivity. For
chlamydia the time after micturition do not seem to
matter, but for M. genitalium two hours is conventional.
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A urinary tract infection (UTI) is rare in young males,
and screening for a UTI in young men with urethritis is not
indicated. If the patient complains of severe dysuria,
haematuria (microscopic or macroscopic), nocturia, urinary
frequency, urgency, or is at low risk for a sexually transmit-
ted infection, a urinary dipstick analysis on a mid-stream
urine specimen should be considered and a mid-stream
urine sent for culture and sensitivities [40]. If a UTI is
found, young men should be investigated for urinary
tract abnormalities. Use of a leucocyte esterase dipstick
on the remains of the FVU specimen is not recom-
mended for diagnosis of NGU, since it does not have
adequate sensitivity to be considered a reliable rapid
diagnostic test [41]. Symptomatic patients negative in
routine NAAT should be referred to a centre which
has microscopy available.
Symptomatic patients with a normal urethral
smear
Treatment without etiological diagnosis or verifying the
presence of urethritis is not recommended. The sensitivity
of the smear test for diagnosing urethritis is affected by
the period since last passing urine. The optimum time to
ensure a definite diagnosis in a symptomatic man is not
known, 2–4 hours is conventional. If urethral smear is
normal and all specific tests are negative, the patient can
be advised to re-attend for an early morning smear (EMS)
if his symptoms do not settle. He should hold his urine
overnight and attend not having voided urine. It is good
practice to advise the patient to take their last drink about
8 pm and to void about 3 hours later in order to help
avoid waking with a full bladder.
Complications
In men younger than 40 years-of-age with acute epididy-
mitis, C. trachomatis is the major non-gonococcal patho-
gen. The role of genital mycoplasmas and ureaplasmas in
the development of acute epididymitis remains to be
determined [42].
Sexually acquired reactive arthritis is infrequent and
depends on the prevalence of HLA B27 in the popula-
tion [43].
Treatment
The most important step in syndromic management of ur-
ethritis is determining whether N. gonorrhoeae is present
during the initial clinic visit. Despite some concerns about
sensitivity, stained urethral smears for microscopic identifi-
cation of N. gonorrhoeae is recommended for concurrently
documenting inflammation and the presence of intracellu-
lar diplococci [31]. Subjects without signs of N. gonorrhoeae
infection are managed syndromically. In men with severe
symptoms the treatment should be initiated as soon as the
diagnosis is made, without waiting for the laboratory test
results. In men with mild symptoms, a potential option is
to review the patient after 3–7 days, when the results of the
NAAT(s) are available, as sometimes urethritis can resolve
without treatment [44]. If laboratory tests are positive, or in
the case of persistent microscopic urethritis, appropriate
antimicrobial treatment, depending on which microorgan-
ism is detected, can then be administered at the second visit
[45]. If the laboratory tests are negative, only treat if pa-
tient has symptoms and microscopic evidence of ureth-
ritis, or observable purulent or muco-purulent discharge
on examination.
Ideally, treatment should be effective (microbiological
cure >95 %), easy to take (not more than twice daily), with
a low side effect profile, and minimal interference with
daily lifestyle. However, assessing treatment efficacy is not
straightforward. Detectable inflammation may persist for
an unknown length of time without persistent infection,
and persistent infection may not result in persistent NGU
[15, 46–48]. Two recent randomised controlled trials from
the United States observed that the clinical response rate
of doxycycline 100 mg x 2 for one week and azithromycin
1 gram stat was the same [49, 50].Mycoplasma genitalium
treatment failure was extremely common. A meta-analysis
of chlamydia treatment options showed a slightly better
cure rate of 3 % with doxycycline compared with single
dose azithromycin for uncomplicated chlamydia infection,
but a 7 % better cure rate with doxycycline for clinical ur-
ethritis [51].
There are two regimens for azithromycin treatment,
single one gram dose, or a five days course – 500 mg day
one followed by 250 mg day 2–5. Single dose azithromy-
cin is thought to induce macrolide resistance in M. geni-
talium to a higher extent than the five days treatment
[52], and should be avoided if M. genitalium is not ruled
out. An initial dosage of one gram azithromycin followed
by 250 mg day 2–5 has also been suggested. However,
there are no randomized studies comparing the different
regimens in men with acute NGU so the recommenda-
tion to use a 5 day regimen with 1 gram initial dosage is
based on expert opinion alone.
Doxycycline has a somewhat higher cure rate in C.
trachomatis than azithromycin [49, 50], cures 20–40 %
of M. genitalium without inducing macrolide resistance,
and should be used as first line treatment.
Azithromycin is widely used as first line treatment for
NGU, but seems to have contributed to the increasing M.
genitalium resistance. Azithromycin, especially the single 1
gram regimen, will induce macrolide resistance in some M.
genitalium strains [52], and will cure only the macrolide
susceptible strains. Thus, without a test of cure (TOC) for
M. genitalium and subsequent moxifloxacin treatment of
treatment failures, the macrolide resistant strains will be se-
lected and further spread. As a consequence, the propor-
tion of macrolide resistant strains in the population will
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increase. The extensive use of azithromycin 1 gram for
treatment of NGU without a TOC for M. genitalium may
explain the declining cure rates [49]. In Greenland, with a
small population of 55,000 inhabitants, a very high inci-
dence of NGU and extensive use of single dose azithromy-
cin, the macrolide resistance rate of M. genitalium has been
shown to be 100 % [53], with a high and comparable inci-
dence of chlamydia andM. genitalium.
Lymecycline or tetracycline hydrochlorine do not in-
duce photosensitivity and can be prescribed if sun ex-
posure cannot be avoided [54].
Sexual contacts/partners
All sexual partners at risk should be assessed and offered
epidemiological treatment, maintaining patient confidenti-
ality. The duration of “look back” is arbitrary; 4 weeks is
suggested for symptomatic men. However, 12 months has
been suggested for chlamydia [55]. Partner(s) notification
and management should be carried out with sensitivity,
considering socio-cultural issues and avoiding stigma.
Current partner(s) should be tested and treated and
the patient advised not to be sexually active until one
week after both have initiated treatment.
If C. trachomatis, M. genitalium or N. gonorrhoeae are
detected, it is important to ensure that all sexual part-
ner(s) potentially at risk have been notified.
Follow up for patients with NGU
All patients should be followed up to ensure completion
of partner notification and ensure they are free of symp-
toms. This follow up can be done by telephone.
Test of cure samples should be collected no earlier than
three weeks after start of treatment in those who tested
positive for M genitalium [49, 56–58]. A repeat test for
chlamydia may be recommended after 3–12 months in
order to detect reinfections. Patients who remain symptom-
atic should be asked to return to the clinic and retreated
with appropriate regimen (see below) and the possibility of
re-infection explored.
Management and diagnosis of recurrent NGU
Ensure that the patient has completed the initial course of
therapy and that reinfection is not a possible cause. Only
treat if patient has symptoms and microscopic evidence of
urethritis, or observable purulent or muco-purulent dis-
charge on examination. Reassure asymptomatic patients
that no further test or treatment is necessary.
Gram or methylene blue stained urethral smear should
be taken only in men who are symptomatic. If symptomatic
and normal microscopy an EMS is recommended. Con-
sider testing for Trichomonas vaginalis using a NAAT if
available, and testing for M. genitalium including screening
for macrolide resistance if identified. Symptomatic patients
negative on routine NAAT without an obvious discharge
should not be retreated without microscopic confirmation,
and should be referred to a centre which has microscopy
available.
Persistent NGU
The aetiology of persistent NGU is probably multifactorial
with an infectious agent being identified in <50 % of cases
[11]. M. genitalium has been identified in 20–40 % [6–8],
[11] and C. trachomatis in 10–20 % in men treated with
azithromycin 1 g [49]. U. urealyticum may also play a role
in some men [15–17]. Trichomonas vaginalis can be iden-
tified in up to 10 % in populations where it is endemic,
but is rare in Western Europe [12]. Recurrent herpes sim-
plex virus infection should be considered, as this can
cause dysuria without signs outside the urethra [24].
Any treatment of persistent NGU should cover M.
genitalium, T. vaginalis and anaerobes, if not tested and
treated for at initial presentation.
As there is no evidence that female partners of men with
persistent/recurrent NGU are at increased risk of pelvic in-
flammatory disease, the historical advice has been that they
do not need to be retreated if treated appropriately at first.
However, in view of the emerging evidence that persistence
of M. genitalium post azithromycin may occur in 20 to
40 % of men and women and doxycycline is < 50 % effective
[49], it is likely that re-treatment of both the sexual partner
and index case will be beneficial if persistent/recurrent
NGU in the index case resolves following extended therapy
but subsequently recurs. For a male partner this would be
the same. This remains an area where further research is
needed.
Treatment of persistent or recurrent NGU
If reinfection is unlikely at follow-up, the patient has com-
pleted the initial course of therapy, is symptomatic and an
observable discharge is present or microscopic evidence of
urethritis is confirmed, re-treatment should be given. Any
treatment of persistent NGU should cover M.
genitalium and T. vaginalis and/or bacterial vaginosi-
sassociated bacteria. However, evidence for the following
recommendations is limited, and is based on clinical ex-
perience and guidelines [59, 60]. If doxycycline was pre-
scribed as first line therapy, switch to Azithromycin
500 mg or 1gram day one, then 250 mg once daily for
4 days plus metronidazole 4–500 mg twice daily for
5 days. If azithromycin was prescribed as first line ther-
apy, doxycycline 100 mg twice daily for 7 days plus
metronidazole 4–500 mg twice daily for 5–7 days should
be prescribed. However, if positive for M. genitalium at
TOC after azithromycin treatment without suspected re-
infection, or in case of positive macrolide resistant test,
Moxifloxacin 400 mg orally once daily for 7–14 days
should be given.
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Moxifloxacin should be used with caution and re-
served for treatment failures which are thought second-
ary to macrolide resistant M. genitalium, because of rare
but serious adverse hepatic reactions. In patients having
contracted M. genitalium infection in South-East Asia,
dual resistance to both macrolides and quinolones is
currently around 10 %. Such infections are difficult to
treat and only pristinamycin (registered in France) has
proven effective on a case basis [61].
Continuing symptoms
There is only limited evidence on how best to manage pa-
tients who either remain symptomatic following a second
course of treatment or who have frequent recurrences
after treatment. Reassure asymptomatic patients that no
further test or treatment is necessary.
To guide management, testing for M. genitalium, in-
cluding macrolide resistance test, is essential. All sexual
partners should be treated concurrently with the same
antibiotic regimen which was effective in the index [62].
Recurrent herpes simplex urethritis should be ruled
out, especially if the main symptom is dysuria, and many
monocytes are seen in the smear [23, 24].
Chronic abacterial prostatitis and the chronic pelvic pain
syndrome and psychosexual causes should be considered in
the differential diagnosis [62, 63]. Chronic pelvic pain syn-
drome is a complex condition which overlaps with chronic
urethritis and a biopsychosocial, holistic management strat-
egy incorporating evidence-based pharmacotherapy has re-
cently been demonstrated to be effective in managing such
patients [64, 65].
For men with persistent or recurrent urethritis, there
is currently no evidence that re-treatment of an appro-
priately treated sexual partner is beneficial (see above).
However, it would be prudent to retreat the partner if
the man with chronic NGU is cured following extended
therapy but subsequently recurs on sexual intercourse.
In this scenario the sexual partner, if female, should be
examined and tested for Trichomonas vaginalis and bac-
terial vaginosis (BV), regardless of symptoms, and both
should be retreated. Doxycycline may be more effective
than azithromycin against the newly identified BV-
associated bacteria [27].
Urological investigation is usually normal and is not
recommended unless the patient has urinary flow prob-
lems [62, 63].
Conclusions
In patients presenting with symptoms of urethritis, the
diagnosis should be confirmed by microscopy in order
to demonstrate an excess of PMNLs in a stained smear
and rule out gonorrhoea. Detection of N. gonorrhoeae,
C. trachomatis and for M. genitalium using a NAAT is
indicated in all patients. If viral or a protozoan aetiology
is suspected, HSV, adenovirus and T. vaginalis should
also be tested for using a NAAT, if available. Syndromic
treatment should be given on confirmation of the
diagnosis in men with marked symptoms. Treatment
options are doxycycline 100 mg x 2 for 7 days or
azithromycin 1 gram or, 1.5 grams over 5 days. Although
azithromycin 1gram continues to be recommended in
national guidelines it is associated with development of
M. genitalium macrolide resistant strains and 500mgs
then 250mgs od for 4 days (1.5 gram) may be a more
sensible option. For men in whom M. genitalium is de-
tected a repeat NAAT test is indicated no earlier than
three weeks after start of treatment. For those men with
persistent infection, moxifloxacin 400 mg 7–14 days is
indicated. Current partner(s) should be tested and
treated with the same treatment regimen given to the
index case. They should abstain from intercourse until
completion of treatment. Persistent or recurrent NGU
must be confirmed with microscopy. Reinfection and
compliance should be considered as possible reasons for
treatment failure. The following treatment options are
based on clinical experience and expert opinion. If doxy-
cycline was given as first line therapy, azithromycin 1.5
grams over five days plus metronidazole 4–500 mg twice
daily for 5–7 days should be given. If azithromycin was
prescribed as first line therapy, doxycycline 100 mg x 2
for one week plus metronidazole should be given. Moxi-
floxacin 400 mg orally once daily for 7–14 days can be
used if macrolide resistant M. genitalium infection is
suspected.
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